Neuromagen Pharma is a pharmaceutical company developing a new class of innovative small molecules which activate Telomerase Reverse Transcriptase (TERT) – an enzyme which plays a major role in preventing cellular senescence.
Our goal is to develop drugs which will delay the onset, and the progression of neurodegenerative diseases and specifically of ALS and improve and extend patients’ lives
Telomerase is a key enzyme for cell lifespan and survival that prevents telomere shortening and the subsequent cellular senescence that is observed after many rounds of cell division.
In addition to its role in telomer re-elongation which increases the cell lifespan, Telomerase catalytic protein component, Telomerase Reverse Transcriptase (TERT), possesses non-canonical functions that enhances the ability of cells and tissues to cope with various cellular damages including oxidative stress.
The neuroprotective effects of telomerase reverse transcriptase (TERT) in the brain and spinal cord were previously demonstrated by us and by others.
We are developing a family of synthetic small molecules (AGS) which activate TERT transcription. Our compounds demonstrated remarkable therapeutic results in various murine models of neurodegenerative diseases, in a dose and time-dependent manner.
In the hSOD1 Tg
murine models of ALS, treatment with AGS-499 delayed the onset and progression of the disease, increased the survival of motor neurons in the mice spinal cord, and increased survival of the mice
When tested on primary murine hippocampal neurons which were subjected to amyloid beta toxicity, treatment with AGS resulted in increased neuronal survival
In-vitro testing of AGS
effects on human mesenchymal stem cells derived from ALS and MS patients demonstrated increased survival and ameliorated oxidative
stress
In the 5XFAD murine
model of Alzheimer
Disease, AGS treatment reduced amyloid beta
plaque burden and
improved cognitive
behavior
Founder, CEO & CSO
Chief Operating Officer
Senior Clinical and Regulatory Advisor
Eitan E, Tichon A, Gazit A, Gitler D, Slavin S, Priel E.
EMBO Mol Med. 2012 Apr;4(4):313-29. doi: 10.1002/emmm.201200212. Epub 2012 Feb 20.
Tichon A, Eitan E, Kurkalli BG, Braiman A, Gazit A, Slavin S, Beith-Yannai E, Priel E.
Curr Mol Med. 2013 Jul;13(6):1010-22. doi: 10.2174/1566524011313060013.
Baruch-Eliyahu N, Rud V, Braiman A, Priel E.
Sci Rep. 2019 Dec 2;9(1):18118. doi: 10.1038/s41598-019-54741-7.
18/10/2021
10/10/2021
01/10/2021
23/06/2022
11/05/2022
05/05/2022
21/03/2022
09/02/2022
18/10/2021
10/10/2021
01/10/2021
23/06/2022
11/05/2022
05/05/2022
Beer Sheva High Tech Park, 77 HaEnergya St.
P. O. Box 5316, Beer Sheva, Israel
© 2021 Neuromagen Pharma
Design & Development imarkimage
